Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company focused on developing innovative cancer therapies, announced that its CEO and Chairman, Dr. Vuong Trieu, will present at the OTCQB Virtual Investor Conference on August 6, 2026, at 2:30 p.m. ET. The presentation will offer investors an opportunity to engage in a live question-and-answer session, providing a platform for the company to highlight its recent progress and strategic initiatives.
The company plans to discuss the advancement of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort, a key milestone in the clinical development of this therapy. Additionally, Oncotelic will detail the expansion of its European clinical sites, which underscores its commitment to broadening the reach of its clinical programs. The presentation will also cover the validation of its Deciparticle(TM) platform through peer-reviewed publications, a testament to the scientific rigor behind its drug delivery technology.
Oncotelic’s scalable cGMP manufacturing capabilities and ongoing development of its AI-driven drug discovery, robotics, and nanomedicine platforms are also set to be featured. These advancements are integral to the company’s mission of accelerating development and improving patient outcomes. According to the company, these technologies aim to enhance precision medicine and RNA therapeutics, positioning Oncotelic at the forefront of cancer treatment innovation.
For investors and interested parties, the full press release detailing the conference participation is available at https://nnw.fm/fGHUt. The company’s latest news and updates can be found in its newsroom at https://nnw.fm/OTLC.
Oncotelic Therapeutics is a clinical-stage biotechnology company dedicated to developing therapies for cancer and other serious diseases. Its portfolio includes clinical-stage oncology assets, the proprietary Deciparticle drug delivery technology, AI-enabled drug discovery platforms, and scalable GMP manufacturing capabilities. The company’s focus on precision medicine and advanced nanomedicine delivery is designed to accelerate development while improving patient outcomes.
The OTCQB Virtual Investor Conference serves as a venue for public companies to present their investment highlights to a broad audience of investors. Oncotelic’s participation underscores its commitment to transparency and its proactive engagement with the investment community. The live Q&A session will allow investors to gain deeper insights into the company’s strategies and future plans.
As Oncotelic continues to advance its pipeline and innovate across multiple platforms, the upcoming presentation is expected to provide a comprehensive overview of its progress and the potential impact of its technologies on cancer treatment. With a focus on delivering actionable intelligence, the company aims to demonstrate how its integrated approach could reshape therapeutic paradigms.
